Italy latest to scrutinise safety of gene therapy
This article was originally published in Clinica
Executive Summary
Italy has announced a temporary ban on new patients joining approved gene therapy trials, after a French patient being treated for x-linked severe combined immunodeficiency (X-SCID) developed leukaemia. It follows similar reactions by the regulatory authorities of France, Germany and the US. The UK, however, has stopped short of halting gene therapy research, in the belief that the benefits outweigh the risks. It will, however, monitor developments, review similar trials and issue advice accordingly.
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.